NCT00684645 - Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT® | Biotech Hunter

Enrollment

186

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG

SUTENT

SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.

Trial Locations (20)

26204

Pfizer Investigational Site, Nová Ves pod Pleší

625 00

Pfizer Investigational Site, Brno

656 53

Pfizer Investigational Site, Brno

656 91

Pfizer Investigational Site, Brno

430 12

Pfizer Investigational Site, Chomutov

370 87

Pfizer Investigational Site, České Budějovice

735 06

Pfizer Investigational Site, Fryštát

500 05

Pfizer Investigational Site, Hradec Králové

586 33

Pfizer Investigational Site, Jihlava

460 63

Pfizer Investigational Site, Liberec

741 01

Pfizer Investigational Site, Nový Jičín

703 84

Pfizer Investigational Site, Ostrava

708 52

Pfizer Investigational Site, Ostrava

532 03

Pfizer Investigational Site, Pardubice

301 00

Pfizer Investigational Site, Pilsen

100 34

Pfizer Investigational Site, Prague

128 08

Pfizer Investigational Site, Prague

140 59

Pfizer Investigational Site, Prague

150 00

Pfizer Investigational Site, Prague

639 00

Pfizer Investigational Site, Zlín